Download - Toxicity of Therapeutic Agents
![Page 1: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/1.jpg)
TOXICITY OF THERAPEUTIC AGENTS
TOXICITY OF THERAPEUTIC AGENTS
![Page 2: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/2.jpg)
C
OH
O
O C
O
CH3
Acetyl salicylic acid colorless or white in crystalline, powder, or granular form. The chemical is odorless and is soluble in water
SALICYLATE TOXICITY
SALICYLATE TOXICITY
Acetylsalicylic acid is colorless or white in crystalline, powder, or granular form. The chemical is odorless and is soluble in water
![Page 3: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/3.jpg)
Therapeutic DoseTherapeutic Dose
• Therapeutic doses– Pediatric 10-20 mg/kg– Adults 650-1000 mg q 4-6 hrs
• Produce a serum level of 5-10 mg/dL
• Potential Toxic Acute Dose > 150 Mg/Kg
• Serious Toxicity: 300-500 Mg/Kg• Chronic Toxicity: >100 Mg/Kg/Day
• Therapeutic doses– Pediatric 10-20 mg/kg– Adults 650-1000 mg q 4-6 hrs
• Produce a serum level of 5-10 mg/dL
• Potential Toxic Acute Dose > 150 Mg/Kg
• Serious Toxicity: 300-500 Mg/Kg• Chronic Toxicity: >100 Mg/Kg/Day
![Page 4: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/4.jpg)
Salicylates are found in hundreds of OTC medications and in numerous prescription drugs.
Salicylate ingestion is one of the most common causes of drug toxicity.
Salicylate ingestion continues to be a common cause of poisoning in children and adolescents.
The presence of aspirin-containing products as household, is a reason to be a common source of unintentional and suicidal ingestion.
The incidence in children declined due to:1-The use of alternative antipyretics. 2- Repackaging, using CRC3- Salicylates association with Reye’s syndrome
Salicylates are found in hundreds of OTC medications and in numerous prescription drugs.
Salicylate ingestion is one of the most common causes of drug toxicity.
Salicylate ingestion continues to be a common cause of poisoning in children and adolescents.
The presence of aspirin-containing products as household, is a reason to be a common source of unintentional and suicidal ingestion.
The incidence in children declined due to:1-The use of alternative antipyretics. 2- Repackaging, using CRC3- Salicylates association with Reye’s syndrome
![Page 5: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/5.jpg)
PharmacokineticsPharmacokinetics• After ingestion, acetylsalicylic acid is rapidly
converted to salicylic acid. • Salicylic acid is readily absorbed in the stomach and small
bowel. Reach peak levels in 15-60 minutes– 90% bound to albumin in the blood at a dose of 10 mg/dL– 90% metabolized in the liver, 10% unchanged
• At therapeutic doses, salicylic acid is metabolized by the liver and eliminated in 2-3 hours.
• T1/2 = 15-20 minutes
• Metabolites and unchanged drug are filtered and secreted by the kidneys
• After ingestion, acetylsalicylic acid is rapidly converted to salicylic acid.
• Salicylic acid is readily absorbed in the stomach and small
bowel. Reach peak levels in 15-60 minutes– 90% bound to albumin in the blood at a dose of 10 mg/dL– 90% metabolized in the liver, 10% unchanged
• At therapeutic doses, salicylic acid is metabolized by the liver and eliminated in 2-3 hours.
• T1/2 = 15-20 minutes
• Metabolites and unchanged drug are filtered and secreted by the kidneys
![Page 6: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/6.jpg)
MetabolismMetabolism
C O
OH
OH
HO
C O
O
OH
C6H9O6
C O
OH
O C6H9O6
C
NH CH2COOH
O
OH
C
OH
O
OH
C
O
CH3
O
OH
C
OH
O
O C
O
CH3
Salicyluric acid Ether glucuronide Ester glucuronide Gentisic acid
AcetylSalicylicacid
Methylsalicylate
2.5%
pHUrine
Absorbed, Proteinbinding
Salicylic acid
![Page 7: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/7.jpg)
ToxicokineticsToxicokinetics
• 76% bound to albumin at a dose of 40 mg/dL– increased free drug in the blood
• Hepatic enzymes become saturated and elimination follows zero-order kinetics– Functional half-life can be over 20
hours
• 76% bound to albumin at a dose of 40 mg/dL– increased free drug in the blood
• Hepatic enzymes become saturated and elimination follows zero-order kinetics– Functional half-life can be over 20
hours
![Page 8: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/8.jpg)
Saturation will change Elimination Kinetics to Zero-typeSaturation will change Elimination Kinetics to Zero-type
C O
OH
OH
HO
C O
O
OH
C6H9O6
C O
OH
O C6H9O6
C
NH CH2COOH
O
OH
C
OH
O
OH
C
O
CH3
O
OH
C
OH
O
O C
O
CH3
Salicyluric acid Ether glucuronide Ester glucuronide Gentisic acid
AcetylSalicylicacid
Methylsalicylate
2.5%
pHUrine
More ASA AbsorbedDecreased Protein
bindingSalicylic acid
SATURATED
![Page 9: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/9.jpg)
methylsalicylate
Hydrolysis in GI tract, liver, RBC’s
2.5% excreted unchanged in urine (pH independent)
zero order kinetics once saturated
zero order kinetics once saturated
% of free SA bound to albumin decreases as the [serum] increases: 75% bound @ 40mgdL 50% bound @ 75mg/dL
Free tissue SA increases
First order kinetics
![Page 10: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/10.jpg)
Toxicokinetic Parameters
Toxicokinetic Parameters
Therapeutic Over dose
Peak blood level 2 hrs >6 hrs
Protein binding 90% 70-90%
Vd 0.15-0.22 L/kg 0.35 L/kg
Half life 2-4 hrs 18-20 hrs
![Page 11: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/11.jpg)
Delayed AbsorptionDelayed Absorption
Enteric coating Bezoar formation (salicylate
bollus) Salicylate-induced pylorospasm
Gastric outlet obstruction Concomitant ingestion of
sustance which decreases gastric motility
Enteric coating Bezoar formation (salicylate
bollus) Salicylate-induced pylorospasm
Gastric outlet obstruction Concomitant ingestion of
sustance which decreases gastric motility
![Page 12: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/12.jpg)
Clinical Manifestations
Clinical Manifestations
• According to the type of toxicity: Acute toxicity or chronic toxicity– While they both encompass the same signs
and symptoms, their presentation can be clinically differentiated
• In general, the earliest signs and symptoms of toxicity include nausea, vomiting, diaphoresis, and tinnitus with or without hearing loss– Other CNS presentations include vertigo,
hyperventilation, hyperactivity, agitation, delirium, hallucinations which are usually followed by convulsions, lethargy and stupor
– A marked elevation in temperature is a sign of severe toxicity and typically preterminal condition
• According to the type of toxicity: Acute toxicity or chronic toxicity– While they both encompass the same signs
and symptoms, their presentation can be clinically differentiated
• In general, the earliest signs and symptoms of toxicity include nausea, vomiting, diaphoresis, and tinnitus with or without hearing loss– Other CNS presentations include vertigo,
hyperventilation, hyperactivity, agitation, delirium, hallucinations which are usually followed by convulsions, lethargy and stupor
– A marked elevation in temperature is a sign of severe toxicity and typically preterminal condition
![Page 13: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/13.jpg)
Chronic SalicylismChronic Salicylism
• Most common in the elderly-unintentional
• May include any sign consistent with acute toxicity
• May also present as:– Delirium– Dementia– Encephalopathy of unknown origin– Congestive heart failure
• Most common in the elderly-unintentional
• May include any sign consistent with acute toxicity
• May also present as:– Delirium– Dementia– Encephalopathy of unknown origin– Congestive heart failure
![Page 14: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/14.jpg)
Chronic Vs Acute Poisoning Chronic Vs Acute PoisoningAcute Chronic
Age Young Adult Elderly/Infants
Mental Status Initially Normal Altered Dehydration Moderate SevereTime To Diagnosis Short Long
Mortality 2% 25%Morbidity 16% 30%Serum ConcentrationMg/dL
40 - ≥120 30 to ≥80
![Page 15: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/15.jpg)
Mechanism of ToxicityMechanism of ToxicitySalicylate is a metabolic substance Salicylate poisoning is manifested
clinically by disturbances of several organ systems: CNS CVS, pulmonary, hepatic, renal, & metabolic systems.
Salicylates directly or indirectly affect most organ systems in the body by uncoupling oxidative phosphorylation, inhibiting Krebs cycle enzymes, and inhibiting amino acid synthesis.
Salicylate is a metabolic substance Salicylate poisoning is manifested
clinically by disturbances of several organ systems: CNS CVS, pulmonary, hepatic, renal, & metabolic systems.
Salicylates directly or indirectly affect most organ systems in the body by uncoupling oxidative phosphorylation, inhibiting Krebs cycle enzymes, and inhibiting amino acid synthesis.
![Page 16: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/16.jpg)
• These processes all contribute to the development of an elevated anion-gap metabolic acidosis
• Combination of a primary respiratory alkalosis and a primary metabolic acidosis is characteristic of salicylate poisoning, especially in adults
• This picture should make your suspect to the diagnosis of SALICYLATE POISONONG
• These processes all contribute to the development of an elevated anion-gap metabolic acidosis
• Combination of a primary respiratory alkalosis and a primary metabolic acidosis is characteristic of salicylate poisoning, especially in adults
• This picture should make your suspect to the diagnosis of SALICYLATE POISONONG
![Page 17: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/17.jpg)
Normal Energy GenerationNormal Energy Generation
Glucose Pyruvate Kreb’s Cycle CO2
NADH2H2O
ATP
Glycolysis Pyruvate decarboxylase
Oxidative Phosphorelation
![Page 18: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/18.jpg)
Salicylate UncouplingSalicylate Uncoupling
Glucose Pyruvate Kreb’s Cycle CO2
NADH2H2O
ATP
SALICYLATES
ATP
Lactate
Glycolysis Pyruvate decarboxylase
Oxidative Phosphorelation
![Page 19: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/19.jpg)
• Catabolism secondary to the inhibition of ATP K dependent reactions leads to:
1) Increased O2 consumption2) Increased CO2 production3)Accelerated activity of glycolytic
& lipolytic pathways4)Depletion of hepatic glycogen5)Hyperpyrexia
• Catabolism secondary to the inhibition of ATP K dependent reactions leads to:
1) Increased O2 consumption2) Increased CO2 production3)Accelerated activity of glycolytic
& lipolytic pathways4)Depletion of hepatic glycogen5)Hyperpyrexia
![Page 20: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/20.jpg)
• Adult patients with acute poisoning usually present with a mixed respiratory alkalosis & metabolic acidosis
• In children, respiratory alkalosis may be transient or metabolic acidosis may occur early in the course.
• Some patients with mixed acid-base disturbances have normal anion-gap metabolic acidosis– Normal anion-gap acidosis does not exclude
salicylate toxicity.
• Adult patients with acute poisoning usually present with a mixed respiratory alkalosis & metabolic acidosis
• In children, respiratory alkalosis may be transient or metabolic acidosis may occur early in the course.
• Some patients with mixed acid-base disturbances have normal anion-gap metabolic acidosis– Normal anion-gap acidosis does not exclude
salicylate toxicity.
![Page 21: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/21.jpg)
Respiratory System Effects
Respiratory System Effects
• Salicylates cause direct and indirect stimulation of respiration.
• A salicylate level of 35 mg/dL or higher causes increases in rate (tachypnea) and depth (hyperpnea) of respiration.
• Salicylate poisoning may rarely cause noncardiogenic pulmonary edema (NCPE) and acute lung injury in pediatric patients.
• Pulmonary edema has extremely high mortality in both children and adults; if present, hemodialysis should be considered as soon as possible.
• Salicylates cause direct and indirect stimulation of respiration.
• A salicylate level of 35 mg/dL or higher causes increases in rate (tachypnea) and depth (hyperpnea) of respiration.
• Salicylate poisoning may rarely cause noncardiogenic pulmonary edema (NCPE) and acute lung injury in pediatric patients.
• Pulmonary edema has extremely high mortality in both children and adults; if present, hemodialysis should be considered as soon as possible.
![Page 22: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/22.jpg)
Mechanism of ToxicityMechanism of Toxicity
• Difference between children & Adults
• Respiratory center stimulation leads to
tachypnea & hyperpnea.
• Excessive wash of CO2 leads to respiratory
alkalosis which is compensated by renal
excretion of HCO3 • Adult patients with acute poisoning
usually present with a mixed respiratory alkalosis & metabolic acidosis
• Difference between children & Adults
• Respiratory center stimulation leads to
tachypnea & hyperpnea.
• Excessive wash of CO2 leads to respiratory
alkalosis which is compensated by renal
excretion of HCO3 • Adult patients with acute poisoning
usually present with a mixed respiratory alkalosis & metabolic acidosis
![Page 23: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/23.jpg)
Mechanism of Toxicity………Causes of Metabolic AcidosisMechanism of Toxicity………Causes of Metabolic Acidosis
1. Salicylate ion = weak acid which contributes to the acidosis.
2. Dehydration from hyperpnea, vomiting, diaphoresis and hyperthermia contributes to lactic acidosis.
3. Uncoupling of mitochondrial oxidative phosphorylation anaerobic metabolism lactate and pyruvate production.
4. Increased fatty acid metabolism (as a consequence of uncoupling of oxydative phosphorylation) lipolysis ketone formation.
5. In compensation for the initial respiratory alkalosis the kidneys excrete HCO3 which later contributes to the metabolic acidosis.
6. Increased Na & K accompany the initial renal bicarbonate diuresis hypokalemia hydrogen ion shift out of cell to maintain electrical neutrality.
7. Inhibition of liver lactate elimination.8. Renal dysfunction accumulation of SA
metabolites which are acids: sulfuric and phosphoric acids.
1. Salicylate ion = weak acid which contributes to the acidosis.
2. Dehydration from hyperpnea, vomiting, diaphoresis and hyperthermia contributes to lactic acidosis.
3. Uncoupling of mitochondrial oxidative phosphorylation anaerobic metabolism lactate and pyruvate production.
4. Increased fatty acid metabolism (as a consequence of uncoupling of oxydative phosphorylation) lipolysis ketone formation.
5. In compensation for the initial respiratory alkalosis the kidneys excrete HCO3 which later contributes to the metabolic acidosis.
6. Increased Na & K accompany the initial renal bicarbonate diuresis hypokalemia hydrogen ion shift out of cell to maintain electrical neutrality.
7. Inhibition of liver lactate elimination.8. Renal dysfunction accumulation of SA
metabolites which are acids: sulfuric and phosphoric acids.
![Page 24: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/24.jpg)
Mechanism of Toxicity
Respiratory Acidosis
Mechanism of Toxicity
Respiratory Acidosis
Respiratory decompensation from fatigue.
SA induced acute lung injury
Inhibitory effect on respiratory center in severe toxic doses.
Respiratory decompensation from fatigue.
SA induced acute lung injury
Inhibitory effect on respiratory center in severe toxic doses.
![Page 25: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/25.jpg)
Mechanism of Toxicity (cont.)
Mechanism of Toxicity (cont.)
Hypercative state increased energy
demand increased tissue glycolysis and gluconeogenesis
hyperglycemiaHypoglycemia is common in chronic or
late in acute toxicities (due insulin secretion)
Inhibit aminotransferase increased AA Aaciduria
Renal tubular damage lead to proteinuria with sodium and water retention
Hypercative state increased energy
demand increased tissue glycolysis and gluconeogenesis
hyperglycemiaHypoglycemia is common in chronic or
late in acute toxicities (due insulin secretion)
Inhibit aminotransferase increased AA Aaciduria
Renal tubular damage lead to proteinuria with sodium and water retention
![Page 26: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/26.jpg)
Clinical featuresClinical features
CNS: tinnitus, decreased hearing, vertigo, hallucinations, agitation, hyperactivity, delirium, stupor, coma, lethargy, seizures, cerebral edema, SIADH
Hem: hypoprothrombinemia, platelet dysfunction and bleeding small doses inhibition of platelet aggregation
occurs BT. lasts for 4-7 days till new platelets are formed
large doses salicylates are changed in the intestine into a dicumarol like substance interferes with vit. K hepatic synthesis of prothrombin PT
GI: n/v, hemorrhagic gastritis, decreased GI motility, pylorospasm, abnormal LFTs
CNS: tinnitus, decreased hearing, vertigo, hallucinations, agitation, hyperactivity, delirium, stupor, coma, lethargy, seizures, cerebral edema, SIADH
Hem: hypoprothrombinemia, platelet dysfunction and bleeding small doses inhibition of platelet aggregation
occurs BT. lasts for 4-7 days till new platelets are formed
large doses salicylates are changed in the intestine into a dicumarol like substance interferes with vit. K hepatic synthesis of prothrombin PT
GI: n/v, hemorrhagic gastritis, decreased GI motility, pylorospasm, abnormal LFTs
![Page 27: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/27.jpg)
Metabolic: fever, hypoglycemia, hyperglycemia, ketosis, ketonuria, rhabdomyolysis
Pulm: tachypnea, pulmonary edema
Renal: proteinuria, Na and water retention
Volume: diaphoresis and dehydration.
Metabolic: fever, hypoglycemia, hyperglycemia, ketosis, ketonuria, rhabdomyolysis
Pulm: tachypnea, pulmonary edema
Renal: proteinuria, Na and water retention
Volume: diaphoresis and dehydration.
![Page 28: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/28.jpg)
temporal sequence temporal sequence
Early: tinnitus, n/v, diaphoresis + hearing loss (a bit later)
Vertigo, hyperventilation, hyperactivity, agitation, delirium, hallucinations, Sz, lethargy and stupor.
Late: coma (after massive ingestions levels >100mg/dL or co-ingestions)
Severe hyperthermia from uncoupling of oxidative phosphorylation is a preterminal event.
Early: tinnitus, n/v, diaphoresis + hearing loss (a bit later)
Vertigo, hyperventilation, hyperactivity, agitation, delirium, hallucinations, Sz, lethargy and stupor.
Late: coma (after massive ingestions levels >100mg/dL or co-ingestions)
Severe hyperthermia from uncoupling of oxidative phosphorylation is a preterminal event.
![Page 29: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/29.jpg)
Fluid and ElectrolytesDehydration:vomiting & insensible
fluid losses. Hypokalemia & hypocalcemia:
respiratory alkalosis. Hypokalemia:
◦ shifting of K+ into the cells in exchange for H+
◦K loss in the urine and from vomiting with subsequent metabolic alkalosis & bicarbonaturia
CVSHypotension (vasodilatation and
hypovolemia)
Fluid and ElectrolytesDehydration:vomiting & insensible
fluid losses. Hypokalemia & hypocalcemia:
respiratory alkalosis. Hypokalemia:
◦ shifting of K+ into the cells in exchange for H+
◦K loss in the urine and from vomiting with subsequent metabolic alkalosis & bicarbonaturia
CVSHypotension (vasodilatation and
hypovolemia)
![Page 30: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/30.jpg)
Bedside ferric chloride testing: positive test quantitative serum salicylate level.
Bedside ferric chloride testing: positive test quantitative serum salicylate level.
C
OH
O
OH
FeC
OH
O
OH
+ FeCl2Salicylic Acid (Purple colored complex)
![Page 31: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/31.jpg)
InvestigationsInvestigationsPresence of Ketonuria & Hypoglycemia: suspicion of salicylate toxicity
Salicylate concentration: Therapeutic Levels from 15-30 mg/dL
Toxicity begin to appear beyond 30 mg/dL.
A 6-hour salicylate level >100 mg/dL is considered potentially lethal and is an indication for hemodialysis.
In significant ingestions, serum salicylate level should be monitored at least 2 hourly until a peak has been reached; then every 4-6 hrs until the peak falls into the nontoxic range.
ABG, Serum electrolytes, glucose, RFT, LFT, PT, PTT.
Presence of Ketonuria & Hypoglycemia: suspicion of salicylate toxicity
Salicylate concentration: Therapeutic Levels from 15-30 mg/dL
Toxicity begin to appear beyond 30 mg/dL.
A 6-hour salicylate level >100 mg/dL is considered potentially lethal and is an indication for hemodialysis.
In significant ingestions, serum salicylate level should be monitored at least 2 hourly until a peak has been reached; then every 4-6 hrs until the peak falls into the nontoxic range.
ABG, Serum electrolytes, glucose, RFT, LFT, PT, PTT.
![Page 32: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/32.jpg)
TreatmentTreatmentGIT decontamination AC, some authors recommend gastric lavage in all
symptomatic patients regardless of time of ingestion. Repeated doses of charcoal may enhance salicylate elimination.
Whole bowel irrigation is more effective in reducing absorption of aspirin enteric-coated tablets.
Urinary alkalizationHaemodialysis: salicylate levels >90-100 mg/dL after acute overdose >40-50 mg/dL in chronic toxicity severe fluid or electrolyte disturbances inability to eliminate the salicylate.
Supportive treatmentCorrection of hypoglycemia in severe casesCorrection of dehydration and electrolyte disturbances Vitamin K1
GIT decontamination AC, some authors recommend gastric lavage in all
symptomatic patients regardless of time of ingestion. Repeated doses of charcoal may enhance salicylate elimination.
Whole bowel irrigation is more effective in reducing absorption of aspirin enteric-coated tablets.
Urinary alkalizationHaemodialysis: salicylate levels >90-100 mg/dL after acute overdose >40-50 mg/dL in chronic toxicity severe fluid or electrolyte disturbances inability to eliminate the salicylate.
Supportive treatmentCorrection of hypoglycemia in severe casesCorrection of dehydration and electrolyte disturbances Vitamin K1
![Page 33: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/33.jpg)
ACETAMINOPHEN
TOXICITY
ACETAMINOPHEN
TOXICITY
![Page 34: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/34.jpg)
• Widely used in adults & commonly used drug in pediatrics.
• Chemical structure is N-acetyl-p-aminophenol
• Maximum daily dose is 4 g in adults & 90 mg/kg in children.
• A single ingestion of 7.5 g (adult) or more than 150 mg/kg in a child is a potentially toxic dose of APAP.
• Widely used in adults & commonly used drug in pediatrics.
• Chemical structure is N-acetyl-p-aminophenol
• Maximum daily dose is 4 g in adults & 90 mg/kg in children.
• A single ingestion of 7.5 g (adult) or more than 150 mg/kg in a child is a potentially toxic dose of APAP.
![Page 35: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/35.jpg)
Mechanism of ActionMechanism of Action
Central prostaglandin synthetase inhibitor
• analgesic• antipyretic with weak anti-inflammatory
properties.
Central prostaglandin synthetase inhibitor
• analgesic• antipyretic with weak anti-inflammatory
properties.
![Page 36: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/36.jpg)
Metabolic PathwaysMetabolic Pathways
Hepatic glucuronide conjugation(40-65%) 90%
Hepatic sulfate conjugation(20-45%) inactive metabolites excreted in the urine.
Excretion of unchanged APAP in the urine (5%).
Oxidation by Cytochrome oxidase P450 (CYP 2E1, 1A2,
and 3A4) to NABQ (5-15%)
GSH combines with NAPQI nontoxic cysteine/mercaptate conjugates excreted in urine.
Hepatic glucuronide conjugation(40-65%) 90%
Hepatic sulfate conjugation(20-45%) inactive metabolites excreted in the urine.
Excretion of unchanged APAP in the urine (5%).
Oxidation by Cytochrome oxidase P450 (CYP 2E1, 1A2,
and 3A4) to NABQ (5-15%)
GSH combines with NAPQI nontoxic cysteine/mercaptate conjugates excreted in urine.
Hepatic glucuronide conjugation(40-65%)Hepatic sulfate conjugation(20-45%)
![Page 37: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/37.jpg)
Factors affecting Acetaminophrn metabolism
Factors affecting Acetaminophrn metabolism
Upregulation (i.e. induction) of CYP 2E1 enzyme activity lead to more production of NABQ: smoking, barbituates, rifampin, carbamazepine,
phenytoin, INH, + ethanol
Decreased glutathione stores: age, diet, liver disease, and medical conditions such as fasting, gastroenteritis, chronic alcoholism, or HIV disease.
Frequent dosing interval of APAP.Prolonged duration of excessive dosing.
Upregulation (i.e. induction) of CYP 2E1 enzyme activity lead to more production of NABQ: smoking, barbituates, rifampin, carbamazepine,
phenytoin, INH, + ethanol
Decreased glutathione stores: age, diet, liver disease, and medical conditions such as fasting, gastroenteritis, chronic alcoholism, or HIV disease.
Frequent dosing interval of APAP.Prolonged duration of excessive dosing.
![Page 38: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/38.jpg)
In children, sulfation is the primary pathway until age 10-12 years; glucuronidation predominates in adolescents and adults.
In children, sulfation is the primary pathway until age 10-12 years; glucuronidation predominates in adolescents and adults.
![Page 39: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/39.jpg)
Gluthione StoresGluthione Stores
Glutathione stores are determined by:◦ age◦ diet◦ liver disease◦ fasting prior
ingestion◦ chronic
malnutrition (anorexia)
◦ gastroenteritis◦ chronic alcoholism◦ HIV
Glutathione stores are determined by:◦ age◦ diet◦ liver disease◦ fasting prior
ingestion◦ chronic
malnutrition (anorexia)
◦ gastroenteritis◦ chronic alcoholism◦ HIV
Glutathione replacement by sulfhydryl compounds: eating NAC
Glutathione replacement by sulfhydryl compounds: eating NAC
![Page 40: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/40.jpg)
Clinical FeaturesClinical FeaturesPhase 1 (up to 24 hours): Patients typically experience anorexia,
nausea, & vomitingRarely neurologic, respiratory, and cardiac
symptomsPhase 2 (24-48 hours) Rt upper quadrant pain with transaminase
elevation.Phase 3 (3-4 days) Symptoms of hepatic failure with jaundice,
bleeding, or encephalopathy. Only about 3.5% of patients who develop
hepatotoxicity develop fulminant hepatic failure.
Phase 4 (4-14 days)Patients may have complete recovery of liver
function or death.
Phase 1 (up to 24 hours): Patients typically experience anorexia,
nausea, & vomitingRarely neurologic, respiratory, and cardiac
symptomsPhase 2 (24-48 hours) Rt upper quadrant pain with transaminase
elevation.Phase 3 (3-4 days) Symptoms of hepatic failure with jaundice,
bleeding, or encephalopathy. Only about 3.5% of patients who develop
hepatotoxicity develop fulminant hepatic failure.
Phase 4 (4-14 days)Patients may have complete recovery of liver
function or death.
![Page 41: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/41.jpg)
InvestigationsInvestigations
1- Acetaminophen serum concentration:– A history of potentially toxic ingestion.– An unknown amount of APAP.– Altered mental status.– Suicidal attempt
2- LFT: transaminase above 1,000 U/L.
3- RFT: may show evidence of renal failure, which often occurs with hepatic failure. In rare circumstances, renal failure may occur without hepatic failure.
1- Acetaminophen serum concentration:– A history of potentially toxic ingestion.– An unknown amount of APAP.– Altered mental status.– Suicidal attempt
2- LFT: transaminase above 1,000 U/L.
3- RFT: may show evidence of renal failure, which often occurs with hepatic failure. In rare circumstances, renal failure may occur without hepatic failure.
![Page 42: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/42.jpg)
Rumack and Matthew Nomogram
Rumack and Matthew Nomogram
![Page 43: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/43.jpg)
mcg/ml 4 8 12 16 20 24
Hours After Acetaminophen Ingestion
150
5
10
50
500
Rumack and Matthew Nomogram
100
Late
Not valid after 24 hours
![Page 44: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/44.jpg)
Abnormal VIII/V ratio:Factor VIII is produced by endothelial cells
and its production is not impaired by APAPFactor V is produced by hepatocytes and its
production diminishes with hepatocellular necrosis.
Metabolic acidosis may result from:Intravascular volume depletion and lactic acidosis
from dehydration/hypoperfusion.ARFLactic acidosis without evidence of FHF from a direct
effect of acetaminophen inhibition of hepatic lactic acid uptake and metabolism.
Fulminant Hepatic Failure (FHF)
Abnormal VIII/V ratio:Factor VIII is produced by endothelial cells
and its production is not impaired by APAPFactor V is produced by hepatocytes and its
production diminishes with hepatocellular necrosis.
Metabolic acidosis may result from:Intravascular volume depletion and lactic acidosis
from dehydration/hypoperfusion.ARFLactic acidosis without evidence of FHF from a direct
effect of acetaminophen inhibition of hepatic lactic acid uptake and metabolism.
Fulminant Hepatic Failure (FHF)
![Page 45: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/45.jpg)
Poor Prognostic IndicatorsPoor Prognostic Indicators
• pH <7.3
• Hepatic encephalopathy• PT >1.8 times normal.• Serum creatinine >
300mmol/L• Coagulation factor VIII/V
ratio of >30
• pH <7.3
• Hepatic encephalopathy• PT >1.8 times normal.• Serum creatinine >
300mmol/L• Coagulation factor VIII/V
ratio of >30
![Page 46: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/46.jpg)
TreatmentTreatment Gastric lavage: should be done to patients with recent (within
1h) and life-threatening toxicity. Activated charcoal adsorbs APAP, but not with oral NAC
N-Acetyl Cysteine is the antidote:1-Precursor for glutathione. NAC is converted to cysteine, which can
replenish glutathione stores.2- NAC also directly detoxifies acetaminophen toxic metabolite to nontoxic metabolites. 3-NAC can provide a substrate for sulfation
a) Oral NAC: It is effective in preventing hepatotoxicity regardless of the initial acetaminophen level if it is started within 8 hrs of ingestion.
b) Intravenous NAC: IV administration of NAC is recommended for selected patients, including those with GIT bleeding or obstruction, potential fetal toxicity, or an inability to tolerate oral NAC.
Gastric lavage: should be done to patients with recent (within 1h) and life-threatening toxicity.
Activated charcoal adsorbs APAP, but not with oral NAC
N-Acetyl Cysteine is the antidote:1-Precursor for glutathione. NAC is converted to cysteine, which can
replenish glutathione stores.2- NAC also directly detoxifies acetaminophen toxic metabolite to nontoxic metabolites. 3-NAC can provide a substrate for sulfation
a) Oral NAC: It is effective in preventing hepatotoxicity regardless of the initial acetaminophen level if it is started within 8 hrs of ingestion.
b) Intravenous NAC: IV administration of NAC is recommended for selected patients, including those with GIT bleeding or obstruction, potential fetal toxicity, or an inability to tolerate oral NAC.
![Page 47: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/47.jpg)
IRON TOXICI
TY
IRON TOXICI
TY
![Page 48: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/48.jpg)
One of the expected common poisonings in young children. The potential severity is based on the amount of elemental iron ingested.
Iron exerts both local and systemic effects: =Iron is corrosive to the GI mucosa and affects the lungs and liver. =Excess free iron is a mitochondrial toxin leading to disturbances in energy metabolism.
Serum iron levels are useful in predicting the clinical course of the patient.
One of the expected common poisonings in young children. The potential severity is based on the amount of elemental iron ingested.
Iron exerts both local and systemic effects: =Iron is corrosive to the GI mucosa and affects the lungs and liver. =Excess free iron is a mitochondrial toxin leading to disturbances in energy metabolism.
Serum iron levels are useful in predicting the clinical course of the patient.
![Page 49: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/49.jpg)
Clinical Manifestations Clinical Manifestations
Phase I: GIT effects: first 6hrs as hemorrhagic vomiting, diarrhea, and abdominal pain.
Hypovolemia may result from GI losses and contribute to tissue hypoperfusion and metabolic acidosis.
Convulsions, shock, and coma may complicate this phase.
Phase I: GIT effects: first 6hrs as hemorrhagic vomiting, diarrhea, and abdominal pain.
Hypovolemia may result from GI losses and contribute to tissue hypoperfusion and metabolic acidosis.
Convulsions, shock, and coma may complicate this phase.
![Page 50: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/50.jpg)
Diarrhoea Vomiting
Fe
Bloody diarrhoea(Melena)
Bloody vomitus(Hematemesis)
Irritation
Corrosion
Irritation Corrosion
Stage I: 1 -6 hrs
GIT
![Page 51: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/51.jpg)
Fluid Loss
Blood Loss
Stage I: 1 -6 hrs
CVS
Reflex tachycardia
GIT
Released from
damaged GIT tissue
![Page 52: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/52.jpg)
↓ B.P hypoperfusion hypoxia anaerobic lactic à.
Fe →uncoupling oxidation phosphorylation →↓ ATP production.
CNS Lethargy, severe coma or seizures.
Lactic acidosis
Hyperglycemia (at early stage).
RS↑Medullary respiratory
center
Acidosis H+ + HCO3- H2CO3 H2O + CO2 BBB
↑R.R Tachypnea
![Page 53: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/53.jpg)
Phase 2: • 6-12 hrs, may be associated with a
period of "apparent recovery" that may be confusing. – In mild cases, the recovery may
represent true recovery. – In serious ingestions, this phase may
not occur at all. • This phase may represent the time
of iron distribution throughout the body to cause systemic injury.
Phase 2: • 6-12 hrs, may be associated with a
period of "apparent recovery" that may be confusing. – In mild cases, the recovery may
represent true recovery. – In serious ingestions, this phase may
not occur at all. • This phase may represent the time
of iron distribution throughout the body to cause systemic injury.
![Page 54: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/54.jpg)
Phase 3: 12-24 hrs: ferrous ferric iron + unbuffered H+
Mitochondrial accumulation disturbs oxidative phosphorylation metabolic acidosis and cell death.
GIT fluid losses hypovolemic shock and acidosis.
Cardiovascular symptoms: decreased heart rate, myocardial activity, cardiac output.
High anion-gap metabolic acidosis results from: (1)Rise of H+ during conversion of free plasma iron to ferric
hydroxide(2)Free radical damage to mitochondrial lactic acidosis(3)Hypovolemia and hypoperfusion.
Coagulopathy: may be due to• inhibitory effect of free iron on the formation of thrombin• reduced levels of clotting due to hepatic failure.
Phase 3: 12-24 hrs: ferrous ferric iron + unbuffered H+
Mitochondrial accumulation disturbs oxidative phosphorylation metabolic acidosis and cell death.
GIT fluid losses hypovolemic shock and acidosis.
Cardiovascular symptoms: decreased heart rate, myocardial activity, cardiac output.
High anion-gap metabolic acidosis results from: (1)Rise of H+ during conversion of free plasma iron to ferric
hydroxide(2)Free radical damage to mitochondrial lactic acidosis(3)Hypovolemia and hypoperfusion.
Coagulopathy: may be due to• inhibitory effect of free iron on the formation of thrombin• reduced levels of clotting due to hepatic failure.
![Page 55: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/55.jpg)
Uncoupling oxidative phosphorylation
Excretion of
HCO3-
Metabolic
AcidosisFe
↓
Stage III
![Page 56: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/56.jpg)
Phase 4: 2 – 6 Weeks
Phase 4: 2 – 6 Weeks
Hepatic cirrhosis.
Pyloric stricture (pyloric
stenosis) → corrosive action.
Hepatic cirrhosis.
Pyloric stricture (pyloric
stenosis) → corrosive action.
![Page 57: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/57.jpg)
Investigations
Investigations• Serum iron levels.
• TIB (is not important)• Abdominal x-ray: may show
radiopaque tablets.• Deferoxamine challenge test: bind
free iron to be excreted in the urine as ferrioxamine complex, changing the urine to reddish (vin rosé) color, indicating the need for chelation.
• Serum iron levels.• TIB (is not important)• Abdominal x-ray: may show
radiopaque tablets.• Deferoxamine challenge test: bind
free iron to be excreted in the urine as ferrioxamine complex, changing the urine to reddish (vin rosé) color, indicating the need for chelation.
![Page 58: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/58.jpg)
![Page 59: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/59.jpg)
![Page 60: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/60.jpg)
TreatmentTreatment• Appropriate supportive care.• Deferoxamine:
1-Shock 2- Altered mental status 3- Persistent GI symptoms 4- Metabolic acidosis 5- Positive radiographs6-Serum Fe >500 μg/dL or estimated dose greater than 60 mg
elemental iron/kg7-Serum iron level is not available with presence of symptoms.
Deferoxamine may be administered IM or IV infusion but IM is not recommended because it is painful and less iron is excreted. Indications for cessation include significant resolution of shock and acidosis, and acute RDS.
• Patients with acute poisoning may develop Yersinia enterocolitica infection. Yersinia requires iron as a growth factor. Infection can be manifested by abdominal pain, fever, and diarrhea following resolution of iron toxicity.
• Appropriate supportive care.• Deferoxamine:
1-Shock 2- Altered mental status 3- Persistent GI symptoms 4- Metabolic acidosis 5- Positive radiographs6-Serum Fe >500 μg/dL or estimated dose greater than 60 mg
elemental iron/kg7-Serum iron level is not available with presence of symptoms.
Deferoxamine may be administered IM or IV infusion but IM is not recommended because it is painful and less iron is excreted. Indications for cessation include significant resolution of shock and acidosis, and acute RDS.
• Patients with acute poisoning may develop Yersinia enterocolitica infection. Yersinia requires iron as a growth factor. Infection can be manifested by abdominal pain, fever, and diarrhea following resolution of iron toxicity.
![Page 61: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/61.jpg)
BARBITURATE
TOXICITY
BARBITURATE
TOXICITY
![Page 62: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/62.jpg)
Barbiturates are commonly used drugs.
Majority of barbiturate poisonings in adults are suicidal attempts.
In children, the poisoning is usually accidental.
Barbiturate abuse is a common problem and the commonly abused barbiturates
Barbiturates are commonly used drugs.
Majority of barbiturate poisonings in adults are suicidal attempts.
In children, the poisoning is usually accidental.
Barbiturate abuse is a common problem and the commonly abused barbiturates
![Page 63: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/63.jpg)
Clinical Presentation
Clinical Presentation
Grade I: Mild Intoxication1.The patient is drowsy. Impaired judgment,
slurred speech, drunken-like gait, incoordination, nystagmus, & ataxia.
2.Reflex activity and vital signs are not affected.
3.This condition resembles alcohol intoxication without flushed face, and no smell.
4.EEG changes include appearance fast activity of 20-30 c/s (prominent over frontal regions).
Grade I: Mild Intoxication1.The patient is drowsy. Impaired judgment,
slurred speech, drunken-like gait, incoordination, nystagmus, & ataxia.
2.Reflex activity and vital signs are not affected.
3.This condition resembles alcohol intoxication without flushed face, and no smell.
4.EEG changes include appearance fast activity of 20-30 c/s (prominent over frontal regions).
![Page 64: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/64.jpg)
Grade II: Moderate Intoxication1. Depression of consciousness
level. Superficial and deep reflexes are depressed.
2. Pupils may be normal, or small and reactive. Severe hypoxia may produce mydriasis.
3. Respiration is slow but not shallow.
4. EEG changes: fast waves become less regular interspersed with slow activity of 3-4 c/s.
Grade II: Moderate Intoxication1. Depression of consciousness
level. Superficial and deep reflexes are depressed.
2. Pupils may be normal, or small and reactive. Severe hypoxia may produce mydriasis.
3. Respiration is slow but not shallow.
4. EEG changes: fast waves become less regular interspersed with slow activity of 3-4 c/s.
![Page 65: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/65.jpg)
Grade III. Severe Intoxication1.Severe impairment of consciousness level.
Absence of deep tendon reflexes then brainstem reflexes.
2.Respiratory depression. Slow, shallow or irregular respiration. Pulmonary edema and cyanosis.
3.Hypotension. Shock.4.Hypothermia is a frequent finding.5.Paralytic ileus.6.Renal failure (hypotension, anoxia, hypothermia,
direct toxicity on renal tubules.)7.Barbiturate blisters: helpful in the diagnosis of
comatose patient. Clear vesicles and bullae on an erythematous base, skin areas at other pressure sites. In about 5% of acute intoxication, and 50% of deaths.
8.EEG: all electrical activity ceases.
Grade III. Severe Intoxication1.Severe impairment of consciousness level.
Absence of deep tendon reflexes then brainstem reflexes.
2.Respiratory depression. Slow, shallow or irregular respiration. Pulmonary edema and cyanosis.
3.Hypotension. Shock.4.Hypothermia is a frequent finding.5.Paralytic ileus.6.Renal failure (hypotension, anoxia, hypothermia,
direct toxicity on renal tubules.)7.Barbiturate blisters: helpful in the diagnosis of
comatose patient. Clear vesicles and bullae on an erythematous base, skin areas at other pressure sites. In about 5% of acute intoxication, and 50% of deaths.
8.EEG: all electrical activity ceases.
![Page 66: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/66.jpg)
![Page 67: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/67.jpg)
ManagementManagement1- Stabilization of vital functions2- Prevention of absorption.3- Enhancing elimination: a) Forced alkaline diuresis. long-
acting barbiturates.b) Hemodialysis: Indications include: • Abnormal vital signs despite
therapy. • Prolonged coma with clinical
deterioration or complications.• Potentially fatal dose or blood level.c) Hemoperfusion with charcoal is
more efficient than hemodialysis.
1- Stabilization of vital functions2- Prevention of absorption.3- Enhancing elimination: a) Forced alkaline diuresis. long-
acting barbiturates.b) Hemodialysis: Indications include: • Abnormal vital signs despite
therapy. • Prolonged coma with clinical
deterioration or complications.• Potentially fatal dose or blood level.c) Hemoperfusion with charcoal is
more efficient than hemodialysis.
![Page 68: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/68.jpg)
TRICYCLIC
ANTIDEPRESSANT
TOXICITY
TRICYCLIC
ANTIDEPRESSANT
TOXICITY
![Page 69: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/69.jpg)
Uses of TCAsUses of TCAs• Depression• OCD• ADD• panic/phobia/anxiety/eating
d/o, • chronic pain• peripheral neuropathies• nocturnal enuresis• migraine prophylaxis• drug withdrawal
• Depression• OCD• ADD• panic/phobia/anxiety/eating
d/o, • chronic pain• peripheral neuropathies• nocturnal enuresis• migraine prophylaxis• drug withdrawal
![Page 70: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/70.jpg)
• Well absorbed from the GIT, rapidly distributed, and quickly bound to body tissue.
• In overdose, they are absorbed slowly because they are ionized in the acid stomach and they slow the peristalsis dramatically; the drug may remain in the stomach for 12 hours or more.
• Gastric dilatation had been reported.
• They are cathecolamine and serotonin RI
• Well absorbed from the GIT, rapidly distributed, and quickly bound to body tissue.
• In overdose, they are absorbed slowly because they are ionized in the acid stomach and they slow the peristalsis dramatically; the drug may remain in the stomach for 12 hours or more.
• Gastric dilatation had been reported.
• They are cathecolamine and serotonin RI
![Page 71: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/71.jpg)
• Most fatalities ingest more than 1 gram
• Fatalities occur in initial hours usually before arrival to hospital
• Desipramine–Most potent Na-channel blocker–Twice the fatality rate of other
TCA’s–May precipitate cardiotoxicity
without significant antimuscarinic symptoms
• Most fatalities ingest more than 1 gram
• Fatalities occur in initial hours usually before arrival to hospital
• Desipramine–Most potent Na-channel blocker–Twice the fatality rate of other
TCA’s–May precipitate cardiotoxicity
without significant antimuscarinic symptoms
![Page 72: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/72.jpg)
EPIDEMIOLOGYEPIDEMIOLOGY
• TCA Toxicity is nearly 25% of drug toxicities in developed countries
• Amitriptyline (TRIPTIZOL)- 40%• Imipramine (TOFRANIL)- 17%• Doxepin (SINEQUAN, ADAPIN)-14%• Nortriptyline (PAMELOR, AVENTYL)-
12%• Desipramine (NORPRAMINE, PERTOFRANE)-
6%
• TCA Toxicity is nearly 25% of drug toxicities in developed countries
• Amitriptyline (TRIPTIZOL)- 40%• Imipramine (TOFRANIL)- 17%• Doxepin (SINEQUAN, ADAPIN)-14%• Nortriptyline (PAMELOR, AVENTYL)-
12%• Desipramine (NORPRAMINE, PERTOFRANE)-
6%
![Page 73: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/73.jpg)
Mechanisms of Action & Toxicity
Mechanisms of Action & Toxicity
Main effectMain effect Other effectsOther effects
![Page 74: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/74.jpg)
PathophysiologyPathophysiology
• All TCA’s structurally similar
• Multiple toxicologic effects–Anticholinergic (Antimuscarinic)
–α adrenergic blockade–Sodium channel blockage–Antihistaminic–GABA-A receptor antagonist
• All TCA’s structurally similar
• Multiple toxicologic effects–Anticholinergic (Antimuscarinic)
–α adrenergic blockade–Sodium channel blockage–Antihistaminic–GABA-A receptor antagonist
![Page 75: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/75.jpg)
PATHOPHYSIOLOGYPATHOPHYSIOLOGY
• Antimuscarinic
– Central: agitation, delirium, confusion, amnesia, hallucinations, slurred speech, ataxia, sedation, coma
– Peripheral: dilated pupils, blurred vision, ↑HR, ↑temp, ↑BP, ↓oral/bronchial secretions, dry skin, ileus, urinary retention, ↑muscle tone, tremor
• Antimuscarinic
– Central: agitation, delirium, confusion, amnesia, hallucinations, slurred speech, ataxia, sedation, coma
– Peripheral: dilated pupils, blurred vision, ↑HR, ↑temp, ↑BP, ↓oral/bronchial secretions, dry skin, ileus, urinary retention, ↑muscle tone, tremor
![Page 76: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/76.jpg)
PATHOPHYSIOLOGYPATHOPHYSIOLOGY
• α-Adrenergic inhibition– α1>α2 CNS sedation, orthostatic
hypotension, pupillary constriction*
• *NOTE: may present with constricted, dilated or mid-sized
pupils
• α-Adrenergic inhibition– α1>α2 CNS sedation, orthostatic
hypotension, pupillary constriction*
• *NOTE: may present with constricted, dilated or mid-sized
pupils
![Page 77: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/77.jpg)
PATHOPHYSIOLOGYPATHOPHYSIOLOGY
• Amine reuptake inhibition– NE:
• Cardiac dysrhythmias• Sympathomimetic
– 5-HT: • Serotonin syndrome• Myoclonus• Hyperreflexia
• Amine reuptake inhibition– NE:
• Cardiac dysrhythmias• Sympathomimetic
– 5-HT: • Serotonin syndrome• Myoclonus• Hyperreflexia
![Page 78: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/78.jpg)
PATHOPHYSIOLOGYPATHOPHYSIOLOGY
• Na-channel blockade– Inhibits influx of Na+ during
depolarization– EKG:
• PR & QRS prolongation• RAD (↑height R wave in lead AVR, S wave
in lead I)
–
• Na-channel blockade– Inhibits influx of Na+ during
depolarization– EKG:
• PR & QRS prolongation• RAD (↑height R wave in lead AVR, S wave
in lead I)
–
![Page 79: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/79.jpg)
PathophysiologyPathophysiology• Sodium Channel Blockade
– Quinidine-like effect– Inhibits influx of Na+ during
depolarization– Most important factor of mortality in
TCA toxicity– Inhibits fast sodium channels in His-
Purkinje cells– Impairs sodium entry into myocardial
cells– Prolongs depolarization (Phase 0),
decreases contractility–
• Sodium Channel Blockade– Quinidine-like effect– Inhibits influx of Na+ during
depolarization– Most important factor of mortality in
TCA toxicity– Inhibits fast sodium channels in His-
Purkinje cells– Impairs sodium entry into myocardial
cells– Prolongs depolarization (Phase 0),
decreases contractility–
![Page 80: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/80.jpg)
-100
-80
-60
-40
-20
0
20
Phase 0
Phase 1
Phase 2
Phase 3
Phase 4
Na+ ca++
ATPase
mv Cardiac Action Potential
Resting membrane Potential
Na+
m
Na+
Na+Na+Na+Na+
h
K+ca++
K+K+K+
ca++ca++
)Plateau Phase(
K+K+K+ Na+
K+
Dep
olar
izat
ion
![Page 81: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/81.jpg)
Sodium Channel Blockade– Prolonged PR– Widens QRS– Right axis deviation
– Bradycardia- May be attenuated by antimuscarinic effect- Indicates profound sodium channel blockade
Sodium Channel Blockade– Prolonged PR– Widens QRS– Right axis deviation
– Bradycardia- May be attenuated by antimuscarinic effect- Indicates profound sodium channel blockade
![Page 82: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/82.jpg)
![Page 83: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/83.jpg)
PATHOPHYSIOLOGYPATHOPHYSIOLOGY
• Antihistaminic–Central CNS sedation, coma
• GABA-A receptor antagonist–Seizures
• Antihistaminic–Central CNS sedation, coma
• GABA-A receptor antagonist–Seizures
![Page 84: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/84.jpg)
Clinical FeaturesClinical Features
• Varies from mild antimuscarinic to severe cardiovascular collapse
• Up to 70% will have coingestants
• May have rapid progression of coma and cardiovascular collapse
• Varies from mild antimuscarinic to severe cardiovascular collapse
• Up to 70% will have coingestants
• May have rapid progression of coma and cardiovascular collapse
![Page 85: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/85.jpg)
Clinical FeaturesClinical Features• Anticholinergic effects tachycardia, hypertension, fever
mydriasis. Dry red skin, dry mouth. Decreased bowel sounds. Urinary retention. Respiratory depression.
• Central nervous system effects Disorientation. Agitation. Hallucinations.
Pyramidal signs: clonus, positive Babinski sign, hyperreflexia. Myoclonic jerks. Seizures. Coma.
• Effects on cardiac conduction and contractility
Hypotension. Bradychardia. AV block. Cardiac
arrest. ECG prolongation of QRS
• Anticholinergic effects tachycardia, hypertension, fever
mydriasis. Dry red skin, dry mouth. Decreased bowel sounds. Urinary retention. Respiratory depression.
• Central nervous system effects Disorientation. Agitation. Hallucinations.
Pyramidal signs: clonus, positive Babinski sign, hyperreflexia. Myoclonic jerks. Seizures. Coma.
• Effects on cardiac conduction and contractility
Hypotension. Bradychardia. AV block. Cardiac
arrest. ECG prolongation of QRS
![Page 86: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/86.jpg)
• Poorer Prognosis:
–QRS >100ms•Greater likelihood of seizures
–QRS >160ms•Greater likelihood of ventricular dysrhythmias
• Poorer Prognosis:
–QRS >100ms•Greater likelihood of seizures
–QRS >160ms•Greater likelihood of ventricular dysrhythmias
![Page 87: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/87.jpg)
ManagementManagement Assessment and Stabilization: The mainstays:prevention of absorbtion of the
drug & respiratory support.
The first 6 hoursAny patient must be placed immediately on a
cardiac monitor.Stomach emptying: Putting charcoal down the
lavage tube before lavage may further limit the amount of drug absorbed. AC effectively binds TCA and can decrease plasma levels. Late gastric lavage should be performed.
Ventilatory support and careful monitoring of acid-base status
ECG should be obtained quickly to detect changes as tachycardia and QRS prolongation.
Hemoperfusion with AC helps to remove the drug
Assessment and Stabilization: The mainstays:prevention of absorbtion of the
drug & respiratory support.
The first 6 hoursAny patient must be placed immediately on a
cardiac monitor.Stomach emptying: Putting charcoal down the
lavage tube before lavage may further limit the amount of drug absorbed. AC effectively binds TCA and can decrease plasma levels. Late gastric lavage should be performed.
Ventilatory support and careful monitoring of acid-base status
ECG should be obtained quickly to detect changes as tachycardia and QRS prolongation.
Hemoperfusion with AC helps to remove the drug
![Page 88: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/88.jpg)
Indications of Sodium Bicarbonate Therapy
Indications of Sodium Bicarbonate Therapy
• Widened QRS >100ms• Refractory hypotension• Ventricular dysrhythmias
–Improves ▪ Conductivity ▪ Contractility▪ Suppresses ventricular ectopy
• Widened QRS >100ms• Refractory hypotension• Ventricular dysrhythmias
–Improves ▪ Conductivity ▪ Contractility▪ Suppresses ventricular ectopy
![Page 89: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/89.jpg)
Treatment of Specific Complications Coma:35%- supportive care. Physostigmine.
Seizures and Myoclonic Jerks in 10%, they may trigger dysrhythmias. Diazepam. Phenytoin can be used for seizures & conduction problems but not myoclonic jerks. Alkalinization in any patient who is in seizure to minimize CV toxicity.
Cardiovascular Toxicity: Sinus tachycardia is universal in TCA overdose. No reason to treat it unless patient is hypotensive or complicated by HF. Alkalinization of the blood to a pH of 7.5 is probably the best treatment available for tachycardia and other forms of cardiotoxicity.
Treatment of Specific Complications Coma:35%- supportive care. Physostigmine.
Seizures and Myoclonic Jerks in 10%, they may trigger dysrhythmias. Diazepam. Phenytoin can be used for seizures & conduction problems but not myoclonic jerks. Alkalinization in any patient who is in seizure to minimize CV toxicity.
Cardiovascular Toxicity: Sinus tachycardia is universal in TCA overdose. No reason to treat it unless patient is hypotensive or complicated by HF. Alkalinization of the blood to a pH of 7.5 is probably the best treatment available for tachycardia and other forms of cardiotoxicity.
![Page 90: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/90.jpg)
• Conduction Blocks: dose dependent, and QRS prolongation becomes greater the more severe doses. RBBB is also common. QT interval may be prolonged. Alkalinization is the first choice treatment, and QRS will narrow and conduction improves with this therapy.
• Hypotension in 14% of patients, usually accompanied by ventricular blocks and cardiac dysrhythmias. Alkalinization and IV fluid loading are effective. If these fail, epinephrine is desirable, because TCA produce strong -adrenergic blockade. Isoproterenol may worsen hypotension by unopposed -adrenergic effect. Dopamine is effective in high doses, but in low doses gives effects similar isoproterenol.
• Conduction Blocks: dose dependent, and QRS prolongation becomes greater the more severe doses. RBBB is also common. QT interval may be prolonged. Alkalinization is the first choice treatment, and QRS will narrow and conduction improves with this therapy.
• Hypotension in 14% of patients, usually accompanied by ventricular blocks and cardiac dysrhythmias. Alkalinization and IV fluid loading are effective. If these fail, epinephrine is desirable, because TCA produce strong -adrenergic blockade. Isoproterenol may worsen hypotension by unopposed -adrenergic effect. Dopamine is effective in high doses, but in low doses gives effects similar isoproterenol.
![Page 91: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/91.jpg)
DIGITALIS
TOXICITY
DIGITALIS
TOXICITY
![Page 92: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/92.jpg)
• Derived from Digitalis lanata & D.
purpurea.
Used in the treatment of HF & SV
arhythmia (particularly atrial fibrillation &
atrial flutter).
• Digitalis poisoning continues to be a
serious problem in infants and
children due to its wide availability &
narrow therapeutic index.
• Derived from Digitalis lanata & D.
purpurea.
Used in the treatment of HF & SV
arhythmia (particularly atrial fibrillation &
atrial flutter).
• Digitalis poisoning continues to be a
serious problem in infants and
children due to its wide availability &
narrow therapeutic index.
![Page 93: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/93.jpg)
PathophysiologyPathophysiology• Bind to cell membrane reversible inhibition of Na+-K+
ATPase pumpElevated intracellular Na+ increased intracellular Ca++ enhanced cardiac contractions (delayed
after depolarizations & manifest clinically as aftercontractions, such as premature ventricular contractions).
• Digitalis increase phase 4 action potential in myocardial tissue reduction of CV with increased automaticity & ectopic activity.
• It has a negative chronotropic action that is partly a vagal effect and partly a direct effect on the sinoatrial node.
– Digitalis has vagotonic effects, resulting in bradycardia & heart blocks.
• Inhibition of Na+-K+-ATPase in skeletal muscle results in increased extracellular potassium and contributes to hyperkalemia.
• Bind to cell membrane reversible inhibition of Na+-K+
ATPase pumpElevated intracellular Na+ increased intracellular Ca++ enhanced cardiac contractions (delayed
after depolarizations & manifest clinically as aftercontractions, such as premature ventricular contractions).
• Digitalis increase phase 4 action potential in myocardial tissue reduction of CV with increased automaticity & ectopic activity.
• It has a negative chronotropic action that is partly a vagal effect and partly a direct effect on the sinoatrial node.
– Digitalis has vagotonic effects, resulting in bradycardia & heart blocks.
• Inhibition of Na+-K+-ATPase in skeletal muscle results in increased extracellular potassium and contributes to hyperkalemia.
![Page 94: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/94.jpg)
Remember that………..Remember that………..
• Heart rate (chronotropic)
• Contractility (inotropic)
• Conductivity (dromotropic)
• Excitability (bathmotropic).
• Heart rate (chronotropic)
• Contractility (inotropic)
• Conductivity (dromotropic)
• Excitability (bathmotropic).
![Page 95: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/95.jpg)
Clinical Features Clinical Features 1-Cardiovascular Manifestations:Sinus bradycardia and AV blocks are more in
childrenVentricular ectopy is more common in
adults. If automaticity is increased and conduction
is depressed, we must think about digitalis toxicity.
2-CNS Manifestation: Lethargy or drowsiness, or
confusion.Headaches.Hallucinations.Visual changes: chromatopsia & xanthopsia,
transient amblyopia or scotomata, and decreased visual acuity (chronic toxicity).
Seizures (rare).3-Gastrointestinal Manifestations:Nausea, vomiting, Diarrhea, Anorexia/weight
loss or failure to thrive, Abdominal pain
1-Cardiovascular Manifestations:Sinus bradycardia and AV blocks are more in
childrenVentricular ectopy is more common in
adults. If automaticity is increased and conduction
is depressed, we must think about digitalis toxicity.
2-CNS Manifestation: Lethargy or drowsiness, or
confusion.Headaches.Hallucinations.Visual changes: chromatopsia & xanthopsia,
transient amblyopia or scotomata, and decreased visual acuity (chronic toxicity).
Seizures (rare).3-Gastrointestinal Manifestations:Nausea, vomiting, Diarrhea, Anorexia/weight
loss or failure to thrive, Abdominal pain
![Page 96: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/96.jpg)
Factors Increasing Toxicity Hypokalemia or hyperkalemia:
Hypokalemia observed with chronic toxicity or with diuretics. Hyperkalemia is a complication of acute toxicity. The large bulk of skeletal muscles is the source of hyperkalemia.
Hypomagnesemia and hypercalcemia. Drugs: Quinidine, procainamide, amiodarone, Ca+
+ channel blockers, and beta-blockers, diuretics including spironolactone.
Erythromycin & tetracycline inactivatie Eubacterium, which is present in 10% of the population and inactivates digoxin in the GIT.
Renal dysfunction. Hypothyroidism. Hypoxemia. Alkalosis. Myocardial disease.
Factors Increasing Toxicity Hypokalemia or hyperkalemia:
Hypokalemia observed with chronic toxicity or with diuretics. Hyperkalemia is a complication of acute toxicity. The large bulk of skeletal muscles is the source of hyperkalemia.
Hypomagnesemia and hypercalcemia. Drugs: Quinidine, procainamide, amiodarone, Ca+
+ channel blockers, and beta-blockers, diuretics including spironolactone.
Erythromycin & tetracycline inactivatie Eubacterium, which is present in 10% of the population and inactivates digoxin in the GIT.
Renal dysfunction. Hypothyroidism. Hypoxemia. Alkalosis. Myocardial disease.
![Page 97: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/97.jpg)
InvestigationsInvestigations Electrolytes, BUN/creatinine,
magnesium, and calcium: initial K+ levels have better prognostic correlation than either ECG changes or initial serum digoxin level
ECG: Sinus bradycardia and AV conduction blocks are the most common ECG changes in children.
Electrolytes, BUN/creatinine, magnesium, and calcium: initial K+ levels have better prognostic correlation than either ECG changes or initial serum digoxin level
ECG: Sinus bradycardia and AV conduction blocks are the most common ECG changes in children.
![Page 98: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/98.jpg)
Therapeutic Serum Digoxin Level = 0.5-2 ng/mL
Neonates and small infants rarely will develop toxicity at levels less than 4-5 ng/mL
Children without CV disease may tolerate levels up to 10 ng/mL …..may have bradyarrhythmias or conduction delays on ECG
General rule: the smaller the infant, the higher the levels may be before observing toxic effects
Therapeutic Serum Digoxin Level = 0.5-2 ng/mL
Neonates and small infants rarely will develop toxicity at levels less than 4-5 ng/mL
Children without CV disease may tolerate levels up to 10 ng/mL …..may have bradyarrhythmias or conduction delays on ECG
General rule: the smaller the infant, the higher the levels may be before observing toxic effects
![Page 99: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/99.jpg)
Endogenous Digoxinlike Immunoreactive Substance (DLIS)
cause false-positive or elevated digoxin level.
DLIS is observed in:1. Neonates2. Patients with renal insufficiency3. Liver disease or hyperbilirubinemia4. Subarachnoid hemorrhage5. Congestive heart failure6. Diabetes M7. Acromegaly8. Pregnancy9. Spironolactone use. 10.Studies have shown preterms with positive
assays up to age 3 months.
Endogenous Digoxinlike Immunoreactive Substance (DLIS)
cause false-positive or elevated digoxin level.
DLIS is observed in:1. Neonates2. Patients with renal insufficiency3. Liver disease or hyperbilirubinemia4. Subarachnoid hemorrhage5. Congestive heart failure6. Diabetes M7. Acromegaly8. Pregnancy9. Spironolactone use. 10.Studies have shown preterms with positive
assays up to age 3 months.
![Page 100: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/100.jpg)
Treatment Treatment General supportive careIV fluid hydration, oxygenation and
support of ventilation, and correction of electrolyte imbalances.
Forced diuresis is not recommended will not increase renal excretion and can worsen electrolyte abnormalities.
General supportive careIV fluid hydration, oxygenation and
support of ventilation, and correction of electrolyte imbalances.
Forced diuresis is not recommended will not increase renal excretion and can worsen electrolyte abnormalities.
![Page 101: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/101.jpg)
Gastrointestinal decontamination1. Activated charcoal is the preferred
method. – Multiple charcoal doses may be
beneficial.
2. Induced emesis is not recommended because of increased vagal effect.
3. Gastric lavage may be useful early but also can increase vagal effects.
4. Whole bowel irrigation may be useful, but clinical data are lacking.
5. Cholestyramine can interrupt enterohepatic circulation especially in patients with renal insufficiency.
Gastrointestinal decontamination1. Activated charcoal is the preferred
method. – Multiple charcoal doses may be
beneficial.
2. Induced emesis is not recommended because of increased vagal effect.
3. Gastric lavage may be useful early but also can increase vagal effects.
4. Whole bowel irrigation may be useful, but clinical data are lacking.
5. Cholestyramine can interrupt enterohepatic circulation especially in patients with renal insufficiency.
![Page 102: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/102.jpg)
Digoxin-specific antibodies (Fab fragments) 1) Life-threatening arrhythmias
2nd. or 3rd.-degree heart blockventricular tachycardia/fibrillation).
2) Initial potassium level > 5 mEq/l.3) Digoxin serum levels >10 ng/mL at 6-8 h 4) Digoxin serum levels >15 ng/mL in an
acute ingestion5) Ingestion >10 mg in healthy adults or
>4 mg in children.
Digoxin-specific antibodies (Fab fragments) 1) Life-threatening arrhythmias
2nd. or 3rd.-degree heart blockventricular tachycardia/fibrillation).
2) Initial potassium level > 5 mEq/l.3) Digoxin serum levels >10 ng/mL at 6-8 h 4) Digoxin serum levels >15 ng/mL in an
acute ingestion5) Ingestion >10 mg in healthy adults or
>4 mg in children.
![Page 103: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/103.jpg)
Dysrhythmia control1. Fab fragment is considered first line
treatment 2. Phenytoin is the drug of choice for
digoxin-induced arrhythmia. It is effective against SV ectopics as well as ventricular arrhythmias.
– Lidocaine is alternative but is not effective against SV arrhythmias.
3. Quinidine and procainamide are not used as they intensify the AV block.
4. IV calcium is contraindicated absolutely due to increased intracellular Ca in digoxin-toxic patients.
Dysrhythmia control1. Fab fragment is considered first line
treatment 2. Phenytoin is the drug of choice for
digoxin-induced arrhythmia. It is effective against SV ectopics as well as ventricular arrhythmias.
– Lidocaine is alternative but is not effective against SV arrhythmias.
3. Quinidine and procainamide are not used as they intensify the AV block.
4. IV calcium is contraindicated absolutely due to increased intracellular Ca in digoxin-toxic patients.
![Page 104: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/104.jpg)
CALCIUM CHANNEL BLOCKER TOXICITY
CALCIUM CHANNEL BLOCKER TOXICITY
![Page 105: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/105.jpg)
CCB are used for AnginaHypertensionArrhythmiasmigraine prophylaxis.
CCB toxicity is one of the most lethal prescription drug ingestions.
CCB are used for AnginaHypertensionArrhythmiasmigraine prophylaxis.
CCB toxicity is one of the most lethal prescription drug ingestions.
![Page 106: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/106.jpg)
Calcium Channel BlockersCalcium Channel Blockers
• Phenylalkylamines– Verapamil
• Benzothiazepines– Diltiazem
• Dihydropyridines– Nifedipine (Adalat) , felodipine,
nimodipine, nicardipine, amlodipine, lercanidipine
• Phenylalkylamines– Verapamil
• Benzothiazepines– Diltiazem
• Dihydropyridines– Nifedipine (Adalat) , felodipine,
nimodipine, nicardipine, amlodipine, lercanidipine
![Page 107: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/107.jpg)
PATHOPHYSIOLOGYPATHOPHYSIOLOGY
• All existing CCBs function by binding to the L-subtype, voltage-sensitive, slow calcium channels in cell membranes.
• The L-type CCBs decrease the flow of calcium into the cells of the cardiac conduction pathway, which leads to an inhibition of the phase 0 in cardiac pacemaker cells and slows the phase 2 plateau in Purkinje cells, cardiac myocytes, and vascular smooth muscle cells.
• In cardiac muscle and vascular smooth muscle rapid calcium influx causes myosin and actin binding and contraction.
• CCBs inhibit calcium influx leading to decreased myocardial contractility and peripheral arterial vasodilation.
• All existing CCBs function by binding to the L-subtype, voltage-sensitive, slow calcium channels in cell membranes.
• The L-type CCBs decrease the flow of calcium into the cells of the cardiac conduction pathway, which leads to an inhibition of the phase 0 in cardiac pacemaker cells and slows the phase 2 plateau in Purkinje cells, cardiac myocytes, and vascular smooth muscle cells.
• In cardiac muscle and vascular smooth muscle rapid calcium influx causes myosin and actin binding and contraction.
• CCBs inhibit calcium influx leading to decreased myocardial contractility and peripheral arterial vasodilation.
![Page 108: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/108.jpg)
Calcium channels The drugs act from the inner side of the membrane and bind more effectively to open channels.-Drugs act by binding to the alpha-1 subunit
Calcium channels The drugs act from the inner side of the membrane and bind more effectively to open channels.-Drugs act by binding to the alpha-1 subunit
Subunit structure of CaV1 channels (L-type channels)
![Page 109: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/109.jpg)
Pathophysiology Pathophysiology • CCB have 4 cardiovascular effects:
1)Peripheral vasodilatation 2)Negative chronotropy (decreased
heart rate)3)Negative inotropy (decreased
cardiac contractility)4)Negative dromotropy (prolonged
cardiac conduction)
• CCB have 4 cardiovascular effects:
1)Peripheral vasodilatation 2)Negative chronotropy (decreased
heart rate)3)Negative inotropy (decreased
cardiac contractility)4)Negative dromotropy (prolonged
cardiac conduction)
![Page 110: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/110.jpg)
Calcium channel blockersCalcium channel blockers
• Block calcium channels (L-type) in heart and blood vessels– prolong depolarisation
• ↑QRS width– block SA and AV node conduction
• heart block• asystole
– vasodilators– cerebral protection
• Block calcium channels (L-type) in heart and blood vessels– prolong depolarisation
• ↑QRS width– block SA and AV node conduction
• heart block• asystole
– vasodilators– cerebral protection
![Page 111: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/111.jpg)
Calcium Channel BlockersCalcium Channel Blockers
• Hypotension–peripheral vasodilatation and myocardial depression
• Bradycardia–AV and SA node block
• Hypotension–peripheral vasodilatation and myocardial depression
• Bradycardia–AV and SA node block
![Page 112: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/112.jpg)
Other Important Effects
Other Important Effects
• Suppression of insulin release & decreased free fatty acid utilization by the myocardium.
These factors produce hyperglycemia, lactic acidosis, and depressed cardiac contractility.
• Suppression of insulin release & decreased free fatty acid utilization by the myocardium.
These factors produce hyperglycemia, lactic acidosis, and depressed cardiac contractility.
![Page 113: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/113.jpg)
CLINICAL PICTURECLINICAL PICTURE• Children can become symptomatic with
as little as one tablet. In young children, calcium channel blockers have the potential to be fatal with single tablet ingestions.
• Delayed onset of hypotension has been reported in children with extended-release tablet ingestion.
• All children with suspected calcium channel blocker ingestions of any amount should be evaluated in a health care facility and monitored in an ICU setting for signs of delayed toxicity.
• Children can become symptomatic with as little as one tablet. In young children, calcium channel blockers have the potential to be fatal with single tablet ingestions.
• Delayed onset of hypotension has been reported in children with extended-release tablet ingestion.
• All children with suspected calcium channel blocker ingestions of any amount should be evaluated in a health care facility and monitored in an ICU setting for signs of delayed toxicity.
![Page 114: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/114.jpg)
• Hypotension• Bradycardia, with variable
degrees of heart block• Altered mental status or
seizures secondary to hypotension
• Occasional cases of bowel infarction caused by mesenteric underperfusion
• Hypotension• Bradycardia, with variable
degrees of heart block• Altered mental status or
seizures secondary to hypotension
• Occasional cases of bowel infarction caused by mesenteric underperfusion
![Page 115: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/115.jpg)
INVESTIGATIONSINVESTIGATIONS• Blood sugar• ABG• Blood levels are generally not
available.• ECG• Cardiac biomarkers, such as
troponin I, may help differentiate drug-induced bradycardia from ischemic causes.
• Blood sugar• ABG• Blood levels are generally not
available.• ECG• Cardiac biomarkers, such as
troponin I, may help differentiate drug-induced bradycardia from ischemic causes.
![Page 116: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/116.jpg)
Management Management Prehospital Care: • Rapid transport before the patient
deteriorates is crucial. Empiric use of glucagon (5-15 mg IV) may be warranted for patients with an unknown overdose presenting with bradycardia or hypotension.
• Consider using calcium only if a witness confirms a calcium channel blocker overdose.
• Treat hypotension with fluid boluses. If profound hypotension fails to respond to fluid resuscitation, administer a dopamine or norepinephrine drip. If the patient deteriorates to cardiac arrest from a calcium channel blocker overdose, perform prolonged cardiopulmonary resuscitation (CPR) in the field because patients have survived neurologically intact after an hour of CPR.
• Establish ABCs, obtain IV access, provide oxygen, and monitor closely.
Prehospital Care: • Rapid transport before the patient
deteriorates is crucial. Empiric use of glucagon (5-15 mg IV) may be warranted for patients with an unknown overdose presenting with bradycardia or hypotension.
• Consider using calcium only if a witness confirms a calcium channel blocker overdose.
• Treat hypotension with fluid boluses. If profound hypotension fails to respond to fluid resuscitation, administer a dopamine or norepinephrine drip. If the patient deteriorates to cardiac arrest from a calcium channel blocker overdose, perform prolonged cardiopulmonary resuscitation (CPR) in the field because patients have survived neurologically intact after an hour of CPR.
• Establish ABCs, obtain IV access, provide oxygen, and monitor closely.
![Page 117: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/117.jpg)
• Avoid ipecac syrup.• Administer IV glucagon if hypotension is
present. Administer fluid bolus of normal saline if no evidence of decompensated congestive heart failure exists.
• Atropine may be tried if significant bradycardia occurs; however, heart block is usually resistant to atropine in calcium channel blocker toxicity. Mid-dose dopamine (5-10 mcg/kg/min) may improve heart rate and contractility.
• Administer IV calcium chloride (up to 4 g) and/or glucagon (up to 15 mg) if hypotension persists.
• Consider dopamine or norepinephrine infusion if a long transport time is likely, as permitted by local prehospital care protocols.
• Avoid ipecac syrup.• Administer IV glucagon if hypotension is
present. Administer fluid bolus of normal saline if no evidence of decompensated congestive heart failure exists.
• Atropine may be tried if significant bradycardia occurs; however, heart block is usually resistant to atropine in calcium channel blocker toxicity. Mid-dose dopamine (5-10 mcg/kg/min) may improve heart rate and contractility.
• Administer IV calcium chloride (up to 4 g) and/or glucagon (up to 15 mg) if hypotension persists.
• Consider dopamine or norepinephrine infusion if a long transport time is likely, as permitted by local prehospital care protocols.
![Page 118: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/118.jpg)
• Gastric decontamination
–Gastric lavage –Activated charcoal –Completely asymptomatic patients may be treated with activated charcoal and close observation.
–Whole bowel . To be careful that ileus, bowel obstruction, and bowel ischemia have not occurred.
• Gastric decontamination
–Gastric lavage –Activated charcoal –Completely asymptomatic patients may be treated with activated charcoal and close observation.
–Whole bowel . To be careful that ileus, bowel obstruction, and bowel ischemia have not occurred.
![Page 119: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/119.jpg)
Medical Medical
1)Correction of acidosis 2)Calcium loading 3)Glucagon 4)Insulin-dextrose 5)Atropine 6)Inotropic agents 7)Cardiac pacing
1)Correction of acidosis 2)Calcium loading 3)Glucagon 4)Insulin-dextrose 5)Atropine 6)Inotropic agents 7)Cardiac pacing
![Page 120: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/120.jpg)
Correction of acidosisCorrection of acidosis
–acidosis enhances the effect of verapamil and decreases the effect of calcium
–sodium bicarbonate significantly improved myocardial contractility and cardiac output in a swine model of verapamil poisoning
–acidosis enhances the effect of verapamil and decreases the effect of calcium
–sodium bicarbonate significantly improved myocardial contractility and cardiac output in a swine model of verapamil poisoning
![Page 121: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/121.jpg)
Calcium LoadingCalcium Loading
• Calcium loading appears to be the most effective agent to use in calcium channel blocker poisoning
• It is primarily indicated in patients with heart block (who have usually taken verapamil or diltiazem)
• Calcium loading appears to be the most effective agent to use in calcium channel blocker poisoning
• It is primarily indicated in patients with heart block (who have usually taken verapamil or diltiazem)
![Page 122: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/122.jpg)
GlucagonGlucagon
• Glucagon is a well-accepted antidote for beta-blocker poisoning
• The rationale for its use in CCB poisoning is that it activates myosin kinase independent of calcium flux
• Clinical experience suggests it is less effective in this setting than in beta-blocker poisoning
• Glucagon is a well-accepted antidote for beta-blocker poisoning
• The rationale for its use in CCB poisoning is that it activates myosin kinase independent of calcium flux
• Clinical experience suggests it is less effective in this setting than in beta-blocker poisoning
![Page 123: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/123.jpg)
Insulin-dextrose euglycaemia
Insulin-dextrose euglycaemia
• Insulin infusions should be used to treat hyperglycaemia or hyperkalaemia
• Insulin-dextrose euglycaemia is more effective in animal models than calcium, adrenaline or glucagon
• Effective in a case series of clinically serious poisonings
• Hypotension that is refractory to volume loading, correction of acidosis and calcium salts
• Insulin infusions should be used to treat hyperglycaemia or hyperkalaemia
• Insulin-dextrose euglycaemia is more effective in animal models than calcium, adrenaline or glucagon
• Effective in a case series of clinically serious poisonings
• Hypotension that is refractory to volume loading, correction of acidosis and calcium salts
![Page 124: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/124.jpg)
AtropineAtropine
• Vagal tone is increase by vomiting and gastrointestinal decontamination
• Atropine should be given to all patients who are vomiting or having GI decontamination
• Atropine should be given to all patients with bradycardia
• A response may only occur after calcium loading
• Vagal tone is increase by vomiting and gastrointestinal decontamination
• Atropine should be given to all patients who are vomiting or having GI decontamination
• Atropine should be given to all patients with bradycardia
• A response may only occur after calcium loading
![Page 125: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/125.jpg)
Inotropic agentsInotropic agents
• Dopamine is the initial pressor agent of choice (75% response) for diltiazem overdose
• Isoprenaline produces a therapeutic response in 50% of patients
• Action is predominantly through increasing the frequency of impulses originating in the SA node
• These agents are often ineffective as chronotropic agents when there is a high degree of conduction block
• Dopamine is the initial pressor agent of choice (75% response) for diltiazem overdose
• Isoprenaline produces a therapeutic response in 50% of patients
• Action is predominantly through increasing the frequency of impulses originating in the SA node
• These agents are often ineffective as chronotropic agents when there is a high degree of conduction block
![Page 126: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/126.jpg)
Cardiac pacingCardiac pacing
• Ventricular rather than atrial pacing
• In severe poisoning the heart may fail to capture and pharmacological therapy will still be required
• Ventricular rather than atrial pacing
• In severe poisoning the heart may fail to capture and pharmacological therapy will still be required
![Page 127: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/127.jpg)
LITHIUMLITHIUM
![Page 128: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/128.jpg)
Back Ground & Pharmacokinetics
Back Ground & Pharmacokinetics• Lithium was an additive in 7 Up till American
beverage makers were forced to remove lithium in 1948.
• Lithium is used in the treatment of depressive and bipolar affective disorders.
• The CNS is the major organ system affected, although the renal, GIT, endocrine, and CVS also may be involved.
• Absorbed from the GI tract. • Peak levels occur 2-4 hours postingestion• Lithium intoxication may occur because of its
narrow therapeutic index. • Poisoning may be intentional or unintentional
• Lithium was an additive in 7 Up till American beverage makers were forced to remove lithium in 1948.
• Lithium is used in the treatment of depressive and bipolar affective disorders.
• The CNS is the major organ system affected, although the renal, GIT, endocrine, and CVS also may be involved.
• Absorbed from the GI tract. • Peak levels occur 2-4 hours postingestion• Lithium intoxication may occur because of its
narrow therapeutic index. • Poisoning may be intentional or unintentional
![Page 129: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/129.jpg)
PharmacokineticsPharmacokinetics
• Half-life of a single dose of Li is 12-27 hrs
• The half-life increases to approximately 36 hrs in elderly
• Half-life may be longer with chronic lithium use.
• An estimated 10,000 toxic exposures occur per year. These data indicate a gradual increase over the past 10 years*
• Half-life of a single dose of Li is 12-27 hrs
• The half-life increases to approximately 36 hrs in elderly
• Half-life may be longer with chronic lithium use.
• An estimated 10,000 toxic exposures occur per year. These data indicate a gradual increase over the past 10 years* * From USA
![Page 130: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/130.jpg)
Mode of Action
Mode of Action
• Lithium is similar to sodium• In addition, lithium may inhibit the release of
monoamines from nerve endings and increase their uptake.
• The exact mode of action of lithium in affective disorders is unknown.
• Lithium has a narrow therapeutic ratio.• Blood concentration must be carefully monitored to
avoid toxicity. • Early signs of lithium toxicity are vomiting and
severe diarrhoea followed by tremor, ataxia, renal impairment and convulsions
• Lithium is similar to sodium• In addition, lithium may inhibit the release of
monoamines from nerve endings and increase their uptake.
• The exact mode of action of lithium in affective disorders is unknown.
• Lithium has a narrow therapeutic ratio.• Blood concentration must be carefully monitored to
avoid toxicity. • Early signs of lithium toxicity are vomiting and
severe diarrhoea followed by tremor, ataxia, renal impairment and convulsions
![Page 131: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/131.jpg)
Types of Poisoning Types of Poisoning
131
1. Acute poisoning - Voluntary or accidental ingestion in a previously untreated patient
2. Acute-on-chronic - Voluntary or accidental ingestion in a patient currently using lithium
3. Chronic poisoning - Progressive lithium toxicity in a patient on lithium therapy
![Page 132: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/132.jpg)
Clinical PictureClinical PictureMild-to-moderate toxicity• Generalized weakness• Fine resting tremor• Mild confusion
Moderate-to-severe toxicity• Severe tremor• Muscle fasciculations• Choreoathetosis• Hyperreflexia• Clonus• Opisthotonos• Stupor• Seizures• Coma• Signs of cardiovascular collapse
Mild-to-moderate toxicity• Generalized weakness• Fine resting tremor• Mild confusion
Moderate-to-severe toxicity• Severe tremor• Muscle fasciculations• Choreoathetosis• Hyperreflexia• Clonus• Opisthotonos• Stupor• Seizures• Coma• Signs of cardiovascular collapse
![Page 133: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/133.jpg)
Lithium Toxicity Effects
Lithium Toxicity Effects
133
ACUTE CHRONIC
GI (nausea, vomiting & diarrhoea)
42% 20%
CNS (seizures) delayed Common > 2.mmol/L
Renal Usualy non signifiant
Universal
ECG Normal QT prolongation usual
Thyroid none Hypothyroidism 20%
Recovery Usual, rapid Disability 10% delayed
Level correlation poor Good
Hypertox. 2007
![Page 134: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/134.jpg)
DosingDosing
• Lithium toxicity is dose related• Lithium is minimally protein bound • The therapeutic dose is 300-2700 mg/d with
desired serum levels of 0.7-1.2 mEq/L.• Lithium clear via kidneys. • Most filtered lithium is reabsorbed in the PCT• Reabsorption of lithium is increased and
toxicity is more likely in patients who are hyponatremic or volume depleted, both of which are possible consequences of diuretic therapy.
• Lithium toxicity is dose related• Lithium is minimally protein bound • The therapeutic dose is 300-2700 mg/d with
desired serum levels of 0.7-1.2 mEq/L.• Lithium clear via kidneys. • Most filtered lithium is reabsorbed in the PCT• Reabsorption of lithium is increased and
toxicity is more likely in patients who are hyponatremic or volume depleted, both of which are possible consequences of diuretic therapy.
![Page 135: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/135.jpg)
Tubular Lithium handling
Li+
Li+
THIAZIDES
LOOPAGENTS
![Page 136: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/136.jpg)
Effects of Furosemide (an example)Effects of Furosemide (an example)
• Loop diuretics may increase serum lithium levels and potentiate the risk of lithium toxicity.
• The exact mechanism is unknown but may be related to the sodium loss induced by loop diuresis, which produces a compensatory increase in proximal tubular reabsorption of sodium along with lithium.
• Loop diuretics may increase serum lithium levels and potentiate the risk of lithium toxicity.
• The exact mechanism is unknown but may be related to the sodium loss induced by loop diuresis, which produces a compensatory increase in proximal tubular reabsorption of sodium along with lithium.
![Page 137: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/137.jpg)
Li+
Li+X
Tubular lithium handling:
Effect of Furosemide
![Page 138: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/138.jpg)
TreatmentTreatmentPrehospital Care• Stabilize life-threatening conditions
and initiate supportive therapy.• Obtain IV access with isotonic sodium
chloride solution.• Monitor cardiac function to assess
rhythm disturbances.
Prehospital Care• Stabilize life-threatening conditions
and initiate supportive therapy.• Obtain IV access with isotonic sodium
chloride solution.• Monitor cardiac function to assess
rhythm disturbances.
![Page 139: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/139.jpg)
Treatment (continued...)
Treatment (continued...)
• Gastric decontamination• Gastric lavage• Activated charcoal (for
possible other drugs)• Consider whole bowel
irrigation.• Hypokalemia.
• Gastric decontamination• Gastric lavage• Activated charcoal (for
possible other drugs)• Consider whole bowel
irrigation.• Hypokalemia.
![Page 140: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/140.jpg)
Treatment (continued...)
Treatment (continued...)
• Avoid onset of hypernatremia.• Hemodialysis In general, consider dialysis in
patients with chronic toxicity and serum lithium concentrations higher than 4mEq/L; also consider dialysis in unstable chronic patients with lithium levels higher than 2.5 mEq/L.
Change in mental status assists in determining need for dialysis
• Avoid onset of hypernatremia.• Hemodialysis In general, consider dialysis in
patients with chronic toxicity and serum lithium concentrations higher than 4mEq/L; also consider dialysis in unstable chronic patients with lithium levels higher than 2.5 mEq/L.
Change in mental status assists in determining need for dialysis
![Page 141: Toxicity of Therapeutic Agents](https://reader036.vdocuments.mx/reader036/viewer/2022062516/568129d9550346895d8cade9/html5/thumbnails/141.jpg)
Complications & Prognosis
Complications & Prognosis
• Truncal and gait ataxia• Nystagmus• Hypertonicity• Short-term memory deficits• Dementia (rare)Prognosis• Most cases of lithium toxicity
result in a favourable outcome; however, up to 10% of individuals with severe toxicity
• Truncal and gait ataxia• Nystagmus• Hypertonicity• Short-term memory deficits• Dementia (rare)Prognosis• Most cases of lithium toxicity
result in a favourable outcome; however, up to 10% of individuals with severe toxicity